This open-label, Phase II trial (n=20) will study the effects of a single intravenous (IV) dose of ketamine (35mg/70kg; 0.5 mg/kg over 40 minutes) on cognitive flexibility in adolescents and young adults (ages 16–26) medically hospitalised for anorexia nervosa or atypical anorexia nervosa.
Single-site, single-group study delivering one IV ketamine infusion (0.5 mg/kg over 40 minutes) to medically hospitalised adolescents and young adults with anorexia nervosa or atypical anorexia nervosa to assess effects on learning and cognitive flexibility.
Eating-disorder symptoms and measures of cognitive flexibility will be assessed pre- and post-infusion; investigators hypothesise ketamine will increase cognitive flexibility and improve the ability to form new, positive associations with food.
Single-group single IV infusion of ketamine for medically hospitalised adolescents and young adults with anorexia nervosa or atypical anorexia nervosa.
0.5 mg/kg (≈35 mg per 70 kg) IV infusion over 40 minutes